Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study
HAW Neil, MM Hawkins, PN Durrington, DJ Betteridge… - Atherosclerosis, 2005 - Elsevier
BACKGROUND:: The prognosis from coronary heart disease (CHD) for patients with
heterozygous familial hypercholesterolaemia has improved substantially since the
introduction of HMG Co-A reductase inhibitors (statins), but the effect of lipid-lowering drug
therapy combined with dietary and life style advice on non-coronary mortality and the risk of
fatal cancer is unclear. METHODS:: The cohort of 2871 patients was recruited from 21
outpatient lipid clinics in the UK from 1980 to 1998 and was followed for 22,992 person …
heterozygous familial hypercholesterolaemia has improved substantially since the
introduction of HMG Co-A reductase inhibitors (statins), but the effect of lipid-lowering drug
therapy combined with dietary and life style advice on non-coronary mortality and the risk of
fatal cancer is unclear. METHODS:: The cohort of 2871 patients was recruited from 21
outpatient lipid clinics in the UK from 1980 to 1998 and was followed for 22,992 person …